# Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

> **NCT03883919** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 20 (actual)

## Conditions studied

- Pancreatic Cancer
- Pancreas Cancer
- Cancer of the Pancreas

## Interventions

- **DRUG:** 5-FU
- **DRUG:** Leucovorin
- **DRUG:** Liposomal Irinotecan
- **DRUG:** Paricalcitol
- **PROCEDURE:** Serum and plasma blood samples
- **PROCEDURE:** Tumor biopsy

## Key facts

- **NCT ID:** NCT03883919
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-11
- **Primary completion:** 2021-03-23
- **Final completion:** 2022-07-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03883919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03883919, "Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03883919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*